Ultragenyx Pharmaceutical (RARE) Current Assets (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Current Assets data on file, last reported at $657.0 million in Q1 2026.

• Current Assets for Q1 2026 came in at $657.0 million, down 6.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $657.0 million (down 6.03% YoY), and the FY2025 annual result was $951.0 million, up 16.4% from the prior year.
• Current Assets declined to $657.0 million in Q1 2026 per RARE's latest filing, from $951.0 million in the prior quarter.
• Over five years, Current Assets peaked at $1.0 billion in Q3 2022 and troughed at $596.0 million in Q1 2024.
• A 5-year average of $760.6 million and a median of $719.8 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets plunged 40.83% in 2023, then jumped 37.39% in 2024.
• A 5-year view of Current Assets shows it stood at $883.9 million in 2022, then decreased by 17.16% to $732.2 million in 2023, then advanced by 11.58% to $817.0 million in 2024, then grew by 16.4% to $951.0 million in 2025, then slumped by 30.91% to $657.0 million in 2026.
• Business Quant data shows RARE's Current Assets at $657.0 million in Q1 2026, $951.0 million in Q4 2025, and $643.2 million in Q3 2025.